Pain and emotional well-being outcomes in southwest oncology group-directed intergroup trial S0205: A phase III study comparing gemcitabine plus cetuximab versus gemcitabine as first-line therapy in patients with advanced pancreas cancer Academic Article uri icon

Overview

MeSH Major

  • Adenocarcinoma
  • Antibodies, Monoclonal
  • Antineoplastic Combined Chemotherapy Protocols
  • Deoxycytidine
  • Pain
  • Pancreatic Neoplasms
  • Quality of Life

abstract

  • We observed palliated pain and improved well-being for patients on this trial. However, these improvements were similar in both treatment arms, suggesting that the addition of cetuximab did not contribute to improvement in these HRQL outcomes.

publication date

  • August 2010

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC2917316

Digital Object Identifier (DOI)

  • 10.1200/JCO.2009.25.8285

PubMed ID

  • 20606094

Additional Document Info

start page

  • 3611

end page

  • 6

volume

  • 28

number

  • 22